[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 538,447
  • Shares Outstanding, K 125,512
  • Annual Sales, $ 44,550 K
  • Annual Income, $ -83,780 K
  • EBIT $ -53 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.49
  • Price/Sales 11.97
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 82.04% (+25.52%)
  • Historical Volatility 46.16%
  • IV Percentile 31%
  • IV Rank 9.16%
  • IV High 335.13% on 09/03/25
  • IV Low 56.51% on 08/17/26
  • Expected Move (DTE 3) 0.30 (6.85%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 177
  • Volume Avg (30-Day) 2,173
  • Put/Call OI Ratio 1.26
  • Today's Open Interest 89,039
  • Open Int (30-Day) 70,974
  • Expected Range 4.04 to 4.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.11
  • Number of Estimates 4
  • High Estimate $-0.06
  • Low Estimate $-0.14
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) +21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.56 +21.52%
on 07/29/26
4.69 -7.76%
on 08/11/26
+0.21 (+5.00%)
since 07/17/26
3-Month
3.56 +21.52%
on 07/29/26
5.18 -16.49%
on 06/24/26
+0.19 (+4.62%)
since 05/18/26
52-Week
2.93 +47.65%
on 01/30/26
7.55 -42.70%
on 10/20/25
+0.15 (+3.49%)
since 08/18/25

Most Recent Stories

More News
Aquestive Therapeutics: Q2 Earnings Snapshot

Aquestive Therapeutics: Q2 Earnings Snapshot

AQST : 4.30 (+0.23%)
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026 ...

AQST : 4.30 (+0.23%)
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026 Self-administration pharmacokinetic (PK) results were comparable to clinician-administered...

AQST : 4.30 (+0.23%)
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 4.30 (+0.23%)
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 4.30 (+0.23%)
Aquestive Therapeutics Q1 Earnings Call Highlights

Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026,...

AQST : 4.30 (+0.23%)
Aquestive Therapeutics: Q1 Earnings Snapshot

Aquestive Therapeutics: Q1 Earnings Snapshot

AQST : 4.30 (+0.23%)
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026 Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union,...

AQST : 4.30 (+0.23%)
Aquestive's Cash Runway Depends on Anaphylm Approval That May Not Come This Quarter

Barchart Research What to Expect from AQST Earnings AQST Generated May 12, 2026 Current Price $4.16 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 6.40% Aquestive's Cash Runway Depends on...

AQST : 4.30 (+0.23%)
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 4.30 (+0.23%)

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 4.51
2nd Resistance Point 4.43
1st Resistance Point 4.36
Last Price 4.30
1st Support Level 4.21
2nd Support Level 4.13
3rd Support Level 4.06

See More

52-Week High 7.55
Fibonacci 61.8% 5.79
Fibonacci 50% 5.24
Fibonacci 38.2% 4.69
Last Price 4.30
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.